GNOM News and Press, Global X Genomics & Biotechnology ETF From 06/30/22

OYST has an approved product that is highly competitive against a blockbuster drug. They seem to have executed commercialization pretty well, except in the bottom line. Here, they have abysmally failed to make any money. Oyster Point Pharma, Inc. (OYST) has an approved p...

Results from phase 1b NAFLD study using pemvidutide are to be released 2nd half of 2022;Q3 of 2022 will be 12-week data and Q4 of 2022 will be 24-week data. It is estimated that the global NASH market could be worth $20 billion by 2027. Interim results from the phase 2 MOMENTUM st...

Vertex Pharma develops, manufactures, and commercializes small molecule drugs for patients with serious diseases. The company has obtained approval for several products that treat forms of cystic fibrosis ("CF"). The firm’s drug pipeline includes treatments for sickle cell dise...

On Friday, BioMarin Pharmaceutical received a positive CHMP opinion in Europe for ValRox for Hemophilia type A treatment. According to the last report, the core portfolio looks solid. Vozxogo remains the main driver of revenue growth this year. If approved in Europe, the start...

Results from the phase 3 RESPONSE study, which is using Seladelpar for the treatment of patients with primary biliary Cholangitis, are expected in 2023. PBC patients treated with Seladelpar over a 2-year period saw a decrease in GLOBE PBC Score and improved transplant-free survival. ...

Repare Therapeutics is working in synthetic lethality, where big pharma has shown interest. They have some early data. While things look good, I will wait for more conclusive data before I jump in. For further details see: Repare Therapeutics: Interesting Gene Editing Co...

The first five months of the year marked the worst start for the S&P 500 since 1970 ― and the sixth worst back to 1928. Stock valuations have come down, but company earnings remain solid. Earnings will slow, but 20% is hard to imagine, even in a recession. For fur...

BioCryst Pharmaceuticals shares have been clobbered due to both the bear market and the uncertainty relating to its lead developing drug (BCX9930). I believe that the FDA would remove the partial clinical hold on BCX9930 by either year-end or next year. The lead drug (Orladeyo) is...

Allogene's leadership position in allogeneic CAR-T can be rewarding for early investors. However, being a pioneer has its pitfalls. The company has a decent amount of cash. For further details see: Allogene Therapeutics: Multibagger Potential, But Terribly Risky

Biotechnology exchange traded funds look to build upon their winning streak on Friday as investors observed a double-digit performance jump across a handful of popular funds over the past week. Healthcare as a sector has been the best performing S&P segment of the market over the past wee...